Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06516939

The Application of Bovine Basic Fibroblast Growth Factor Gel in the Treatment of Sensitive Skin

The Application of Bovine Basic Fibroblast Growth Factor Gel in the Treatment of Sensitive Skin

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Sensitive Skin

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Shanghai Skin Disease Hospital

Shanghai, China

Location status: Recruiting

Location contact

Haiyan Zhang, MD PhD

CONTACT

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Sensitive skin with a diagnosis of persistent erythema and a lactate irritation test score of 2-3
  • No related skin care products including bovine alkaline fibroblast growth factor were used within 1 month before participating in the experiment, and photoelectric treatment measures were not carried out
  • Physical sunscreen should be strict during enrollment

Exclusion criteria

  • Children
  • Have serious heart, liver, kidney, and blood system diseases, and severe immunocompromise
  • Patients with mental illness or cancer
  • Those who have received glucocorticoids, calcineurin inhibitors, topical small molecule drugs, antibiotics or tretinoin within 3 months
  • Those who are allergic to basic fibroblast growth factor gel and its components
  • Acute dermatitis of the face and perifolliculitis

Treatment and study plan

bFGF

Drug

Half-face randomized control

Bovine Basic Gel

Drug

Bovine Basic Gel

Primary outcomes

  1. erythema index

    Time frame: 0、1、2、4 week

    The change rate in lesion clearance of face at 1 month after treatment will be measured as the primary outcome

Study contacts

Contact information is provided by the study sponsor or research team.

Haiyan Zhang, MD PhD

CONTACT

[email protected]

18017336573

xiuli Wang, MD PhD

CONTACT

[email protected]

18017336663

Sponsors and collaborators

Lead sponsor

Shanghai Dermatology Hospital

Other

Registry information

Important dates

Study start
2024
Primary completion
2024
Study completion
2024
First posted
Jul 24, 2024
Registry last updated
Jul 24, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.